Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Fineline Cube Aug 5, 2026
Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Fineline Cube Aug 5, 2026
Company Deals

Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing

Fineline Cube Dec 7, 2022

Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of...

Company Deals

Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments

Fineline Cube Dec 7, 2022

China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to...

Policy / Regulatory

NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions

Fineline Cube Dec 7, 2022

The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the...

Company Deals

MaxHealth Biotechnology Completes Series B+ Financing Round

Fineline Cube Dec 7, 2022

Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...

Company Drug

MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe

Fineline Cube Dec 7, 2022

Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...

Company Deals

F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again

Fineline Cube Dec 7, 2022

UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...

Company Deals

ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy

Fineline Cube Dec 6, 2022

Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...

Company Drug

Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 6, 2022

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...

Company Deals

Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform

Fineline Cube Dec 6, 2022

Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...

Hospital

Hainan’s First Integrated Bladder Cancer Center Launched at Provincial Urology Meeting

Fineline Cube Dec 6, 2022

The first Integrated Bladder Cancer Center (IBCC) in Hainan province was inaugurated in Hainan General...

Deals Hospital

United Family Healthcare Partners with HSS for Orthopedic Collaboration

Fineline Cube Dec 6, 2022

United Family Healthcare (UFH), a private comprehensive medical institution based in Beijing, announced an agreement...

Company Medical Device

MicroPort MedBot’s Orthopedic Surgery Robot Receives CE Certification

Fineline Cube Dec 6, 2022

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced receiving a CE certification in Europe...

Company Drug

Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers

Fineline Cube Dec 6, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...

Company Deals

Akeso Biopharma Plans IPO on Shanghai’s STAR Market

Fineline Cube Dec 6, 2022

China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...

Company

Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups

Fineline Cube Dec 6, 2022

Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners...

Company Deals

Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets

Fineline Cube Dec 6, 2022

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...

Company Drug

WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 5, 2022

Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...

Company Drug

Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study

Fineline Cube Dec 5, 2022

China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...

Company Deals Digital

China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma

Fineline Cube Dec 5, 2022

China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...

Company Drug

Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study

Fineline Cube Dec 5, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...

Posts pagination

1 … 628 629 630 … 704

Recent updates

  • Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
  • Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline
  • Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
  • Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
  • Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Company

Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline

Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.